How much does GAVRETO (Pralsetinib Capsules) Cost& price without insurance in China?
GAVRETO® is the commercial brand name of Pralsetinib Capsules, an orally active, highly selective rearranged during transfection (RET) inhibitor developed by Blueprint Medicines and licensed to BeiGene. It exerts anti-tumor activity by specifically inhibiting the kinase activity of RET, thereby blocking downstream signaling pathways and suppressing the proliferation and survival of tumor cells harboring RET fusions or activating mutations.
Main Indications
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET gene fusions;
Treatment of adult patients with advanced or metastatic thyroid cancer harboring RET mutations, including medullary thyroid carcinoma (MTC) and differentiated thyroid carcinoma (DTC).
Common Side Effects
Common adverse reactions: Fatigue, constipation, musculoskeletal pain, hypertension, diarrhea, dry mouth, cough, fever, and peripheral edema.
Laboratory abnormalities: Decreased neutrophil count, decreased hemoglobin, decreased lymphocyte count, increased transaminases, and increased creatinine.
Severe but manageable risks: Interstitial lung disease/pneumonitis, severe hypertension, hepatotoxicity, and hemorrhage.
Approval Status in China
GAVRETO® (Pralsetinib Capsules, 100mg) was officially approved for marketing in China in March 2021. It is currently a prescription drug included in China’s Category B medical insurance.
Buy GAVRETO (Pralsetinib Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
